Participated · Series A · Feb 2026

BrainCheck offers BrainCheck Assess™, an FDA Class II digital cognitive assessment suite that lets clinicians in primary care, neurology, and psychiatry rapidly screen and monitor patients for conditions such as mild cognitive impairment and Alzheimer’s disease. The platform produces standardized, repeatable cognitive data and allows providers to customize testing protocols in English or Spanish. Beyond testing, BrainCheck supplies care-planning workflows that have generated more than 14,000 individualized Care Plans and enabled over 640,000 cognitive assessments to date. More than 500 healthcare organizations, including Bon Secours, UPMC and Springfield Clinic, as well as 46 research hospitals like UT Austin and Stanford, currently use the solution. The company is expanding its enterprise cognitive-care infrastructure to support workflow integration, longitudinal monitoring, and population-scale deployment. It also partners with collaborative-care organizations to deliver comprehensive cognitive-care pathways for practices lacking in-house staffing or infrastructure. Future development includes advanced AI-assisted clinical features aimed at risk-bearing and value-based care environments.

Participated · Series B · Jan 2026

Precede Biosciences is a precision diagnostics and data company that has built a proprietary, automated assay capable of extracting high-resolution, genome-wide transcriptional information from a single blood draw. The platform integrates this assay with advanced machine-learning analytics, enabling researchers and clinicians to profile target expression and pathway activity—critical biomarkers for drug-, radio- and immune-conjugates and other targeted therapies. By providing a multiplex, minimally invasive alternative to tissue biopsies, the company aims to accelerate drug development and ensure patients receive therapies precisely matched to their disease biology. Current commercial traction is described as “rapidly growing,” driven by partnerships with developers of next-generation precision medicines. The fresh financing brings Precede Bio’s total new capital to $83.5 million, giving the company resources to scale its platform and meet rising demand. An expanded investor base with deep diagnostics-commercialization expertise is expected to support health-system adoption and long-term growth.

Participated · Series A · Sep 2025

Penguin Ai’s flagship platform combines task-specific Small Language Models (SLMs), proprietary language models, APIs and out-of-the-box Digital Workers and Agents to automate back-office healthcare workflows such as medical coding, prior authorizations, claims adjudication, appeals management, risk adjustment, chart summarization and payment integrity. The company emphasizes a full-service platform approach rather than point solutions, including tooling to prepare data for AI, pre-built healthcare LLMs, and governance and bias-correction capabilities for security and fairness. Penguin Ai says it has secured key partnerships with health plans, providers and technology organizations and is collaborating with customers to accelerate development of its enterprise-grade platform. Leadership is led by founder and CEO Fawad Butt, the former chief data officer of UnitedHealthcare, Kaiser Permanente and Optum, and the team brings collective experience from major payer, provider and tech organizations. The company positions its technology to reduce the industry’s estimated $1 trillion administrative burden and to lower operational costs while improving accuracy and efficiency. Penguin Ai plans to use recent funding to support hiring, product development, and scaling deployments with payers and providers.

Participated · Series C · Jul 2025

Ultromics, spun out of the University of Oxford, offers EchoGo®, an artificial-intelligence platform that turns routine cardiac ultrasounds into objective diagnostic reports. The system is trained on one of the world’s largest echocardiography datasets and validated against actual patient outcomes, enabling it to identify subtle markers of HFpEF that are frequently missed in standard workflows. EchoGo has already analyzed more than 430,000 echocardiograms and is deployed in hospitals across the United States and the United Kingdom. Clinical studies cited by the company show the software reached a diagnostic decision in 93% of patients versus 40% for traditional HFpEF risk scores, with consistent accuracy across gender, age and risk groups. Ultromics’ technology is reimbursed by public and private payers and is cleared by the U.S. FDA, underscoring its commercial readiness. Backed by multiple investors and health systems, the company aims to make early identification of heart failure a standard part of cardiac care worldwide.

Led · Series B · May 2025

Carta Healthcare provides an AI-powered platform that automates clinical data abstraction and analytics, combining machine learning with deep clinical expertise to extract and structure both structured and unstructured clinical data. Its technology generates actionable insights for health systems and life sciences organizations, streamlining data abstraction processes and reducing labor costs. The company plans to expand its customer footprint—particularly in the life sciences market—and to scale product deployment and operations following its late-2024 acquisition of Realyze Intelligence from UPMC Enterprises. The Realyze Intelligence acquisition added capabilities for rapidly analyzing data and identifying patients who match clinical trials and research studies. Founded in 2017 and headquartered in San Francisco, Carta reports consistent year-over-year growth and says the new capital will support hiring, infrastructure, and expanded market demand. The company’s CFO described Carta as financially healthy and positioned to strengthen its balance sheet and capture market opportunity. Carta Healthcare delivers collection, analysis, and insights into clinical data by providing registry data abstraction, reporting, and analytics to leading health systems. The company combines state-of-the-art technology with a team of experienced clinicians to produce high-quality registry data and associated analytics. By transforming the abstraction process and implementing powerful analytic capabilities, Carta informs data-driven decisions that can improve patient outcomes, reduce data-processing costs, and enable clinicians to spend more time on patient care. The company reports markedly faster data collection, superior data quality, and considerable cost savings for healthcare providers. Carta intends to use the recent funding to scale operations and accelerate product development to make more products accessible to more health systems. The business is focused on enhancing healthcare data processes and analytics to support better patient outcomes and research capabilities. Carta Healthcare provides AI-driven clinical data abstraction technology and services that use natural language processing and machine learning to reduce manual labor in curating trustworthy, actionable datasets. Its platform collects, analyzes, and layers analytic capabilities on clinical data to fuel data-driven healthcare decisions and improve patient care. The company supports the healthcare data registry market by transforming previously manual abstraction processes into automated workflows. Carta plans to use new funding to expand its clinical and technical teams and build new partnerships to make healthcare data more actionable. The company emphasizes making data-driven improvements to care delivery and bringing its solutions to new partners. Carta was founded in 2017 and is headquartered in San Francisco; it announced a recent Series A to accelerate growth.